Regulatory approval

Published by the Health Service Executive. Approved

Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

This is written in the approval document.

Reimbursement

CDS

Citation

Trametinib and Dabrafenib Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed on 26/03/2026, https://healthservice.hse.ie/documents/6732/415_v4_Trametinib_and_DabrafenibTherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HSE (1) BRAF p.V600E Melanoma Dabrafenib, Trametinib
HSE (1) BRAF p.V600K Melanoma Dabrafenib, Trametinib

Contributions

Date Contributor Description
2024-01-16 Van Allen lab Adding HSE approvals for reimbursement to database
2021-12-01 Health Service Executive Indication approved for reimbursement.